Cardiometabolic features of polycystic ovary syndrome

被引：0
|
作者：
Leslie K Hoffman
David A Ehrmann
机构：
[1] LK Hoffman is a Fellow,Department of Medicine
[2] and DA Ehrmann is a Professor of Medicine,undefined
[3] in the Section of Endocrinology,undefined
[4] Diabetes and Metabolism,undefined
[5] University of Chicago,undefined
[6] Chicago,undefined
[7] IL,undefined
[8] USA.,undefined
来源：
Nature Clinical Practice Endocrinology & Metabolism | 2008年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Polycystic ovary syndrome (PCOS) affects up to 10% of women and features a range of hormonal and metabolic abnormalities, many of which are associated with increased cardiovascular risk. The authors of this article urge clinicians to be aware of this risk when dealing with even young women who have PCOS.
引用
收藏
页码：215 / 222
页数：7
相关论文
共 50 条
  • [41] The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome
    Robert Krysiak
    Witold Szkróbka
    Bogusław Okopień
    Pharmacological Reports, 2021, 73 : 261 - 268
  • [42] Serum visfatin as predictive marker of cardiometabolic risk in women with polycystic ovary syndrome
    Rashad, Nearmeen M.
    Abd-Elrahman, M. N. Ayman
    El-Shal, Amal S.
    Amin, Abdelaziz I.
    MIDDLE EAST FERTILITY SOCIETY JOURNAL, 2018, 23 (04) : 335 - 341
  • [43] Cardiometabolic Effects of Chronic Hyperandrogenemia in a New Model of Postmenopausal Polycystic Ovary Syndrome
    Dalmasso, Carolina
    Maranon, Rodrigo
    Patil, Chetan
    Bui, Elizabeth
    Moulana, Mohadetheh
    Zhang, Howei
    Smith, Andrew
    Cardozo, Licy L. Yanes
    Reckelhoff, Jane F.
    ENDOCRINOLOGY, 2016, 157 (07) : 2920 - 2927
  • [44] PREVALENCE OF CARDIOMETABOLIC ABNORMALITIES IN A CLINICAL SAMPLE OF YOUNG WOMEN WITH POLYCYSTIC OVARY SYNDROME
    Gooding, Holly C.
    Stortini, Frank
    Henke, Patrick J.
    DiVasta, Amy D.
    JOURNAL OF ADOLESCENT HEALTH, 2017, 60 (02) : S107 - S108
  • [45] The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment
    Baldani, Dinka Pavicic
    Skrgatic, Lana
    Ougouag, Roya
    Kasum, Miro
    GYNECOLOGICAL ENDOCRINOLOGY, 2018, 34 (02) : 87 - 91
  • [46] Does body weight affect cardiometabolic risk in women with polycystic ovary syndrome?
    Dokras, Anuja
    FERTILITY AND STERILITY, 2019, 111 (01) : 56 - 57
  • [47] Antimullerian hormone levels and cardiometabolic risk in young women with polycystic ovary syndrome
    Feldman, Rebecca A.
    O'Neill, Kathleen
    Butts, Samantha F.
    Dokras, Anuja
    FERTILITY AND STERILITY, 2017, 107 (01) : 276 - 281
  • [48] Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome
    Harmanci, Ayla
    Cinar, Nese
    Bayraktar, Miyase
    Yildiz, Bulent Okan
    CLINICAL ENDOCRINOLOGY, 2013, 78 (01) : 120 - 125
  • [49] The impact of hyperandrogenism in female obesity and cardiometabolic diseases associated with polycystic ovary syndrome
    Barber, Thomas M.
    Vojtechova, Petra
    Franks, Stephen
    HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION, 2013, 15 (03) : 91 - 103
  • [50] The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome
    Krysiak, Robert
    Szkrobka, Witold
    Okopien, Boguslaw
    PHARMACOLOGICAL REPORTS, 2021, 73 (01) : 261 - 268
12345